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Agmatine modulates spontaneous activity
in neurons of the rat medial habenular
complex—a relevant mechanism in the
pathophysiology and treatment of
depression?
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Abstract
The dorsal diencephalic conduction system connects limbic forebrain structures to monaminergic mesencephalic
nuclei via a distinct relay station, the habenular complexes. Both habenular nuclei, the lateral as well as the medial
nucleus, are considered to play a prominent role in mental disorders like major depression. Herein, we investigate the
effect of the polyamine agmatine on the electrical activity of neurons within the medial habenula in rat. We present
evidence that agmatine strongly decreases spontaneous action potential ﬁring of medial habenular neurons by
activating I1-type imidazoline receptors. Additionally, we compare the expression patterns of agmatinase, an enzyme
capable of inactivating agmatine, in rat and human habenula. In the medial habenula of both species, agmatinase is
similarly distributed and observed in neurons and, in particular, in distinct neuropil areas. The putative relevance of
these ﬁndings in the context of depression is discussed. It is concluded that increased activity of the agmatinergic
system in the medial habenula may strengthen midbrain dopaminergic activity. Consequently, the
habenular–interpeduncular axis may be dysregulated in patients with major depression.
Introduction
In the vertebrate brain, the medial habenular complex
(MHb), together with the lateral habenular complex
(LHb), is part of the epithalamus, an evolutionarily con-
served brain region that is originally involved in the cir-
cadian regulation of biological rhythms1. During
mammalian evolution, the habenula acquired additional
functions, including in the context of anxiety and stress
behavior, learning and memory, attention, and reward
processing2–4. Thus, the habenula serves an integral part
in the ﬂow and processing of information from the so-
called “limbic forebrain” to the midbrain5,6, thereby
simultaneously inﬂuencing serotoninergic, dopaminergic,
and cholinergic neurotransmitter systems. With respect
to the morphology of afferent and efferent connections,
however, the medial and lateral habenulae represent dis-
tinct entities7. The two nuclei are uni-directionally con-
nected by axons originating in the MHb and projecting to
the LHb8. The main input to the MHb via the stria
medullaris arises from the triangular septal nucleus and
septoﬁmbral nucleus6,9. The predominant efferent pro-
jection of the MHb via the fasciculus retroﬂexus termi-
nates in the interpeduncular nucleus (K, L), (IPN)5,9. The
IPN, in turn, gives rise to ascending projections to limbic
structures as well as descending projections to midbrain
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raphe nuclei, central gray, and dorsal tegmental nuclei10.
Based on morphology, protein and mRNA expression, ﬁve
subcomponents, namely the superior, inferior, central,
lateral, and commissural subnuclei, have been initially
described in the MHb7,11. More recently, the MHb has
been conceived of as being subdivided into a dorsal
component, essentially containing superior and dorsal
subnuclei, and a ventral component, containing central,
lateral, and medial subnuclei12,13. The different subnuclei
project to different subdivisions of the IPN in a topo-
graphic manner12,14. Accordingly, the ventral IPN sub-
nuclei (IPC and IPI) are selectively innervated by the
medial part of the MHb, whereas the dorsal group of IP
subnuclei is mainly innervated by the central and lateral
MHb subnuclei12.
The MHb subnuclei use different combinations of
neurotransmitter systems11. The superior part is gluta-
matergic and contains neurokinins, the dorsal part of the
central MHb utilizes glutamate and substance P, while the
ventral part of the central MHb as well as the inferior and
lateral MHb are both cholinergic and glutamatergic.
Furthermore, the MHb contains high concentrations of
nicotinic acetylcholine receptors15 as well as GABAB
receptors16,17, the latter indicating the presence of strong
GABAergic inputs9. The MHb–IPN axis is part of
addiction pathways, most notably with participation in
nicotine withdrawal and anxiety18,19.
With respect to dendritic and axonal morphology of
MHb neurons, several different cell types have been
described8. Despite their morphological differences, all
MHb cells recorded in the aforementioned study shared the
same electrical property, namely spontaneous tonic ﬁring of
action potentials at 1–10Hz, which persisted after blocking
of ionotropic glutamate and GABAA/GABAB receptors.
Without blocking synaptic transmission, massive AMPA/
kainate receptor-mediated spontaneous excitatory post-
synaptic potentials (EPSPs), most likely generated by
neighboring MHb cells, were also evident, indicating the
release of glutamate from at least a subpopulation of MHb
neurons. According to a more recent study, cholinergic
neurons account for the spontaneous action potential ﬁring,
whereas peptidergic neurons behave differently20. The
temporal pattern of MHb cell ﬁring can be modulated by a
dual GABAergic synaptic response21. In contrast to the
typical GABAergic inhibition, in the MHb there is a
GABAA receptor-mediated fast excitation
21,22. It is followed
by a slow inhibition due to GABAB receptor activation as
observed in rats at postnatal days 18–25. The GABAergic
synaptic input is apparently exclusively extrinsic, because
GABA-containing terminals, but neither GABA- nor GAD-
containing cell bodies, were observed in the MHb (ref.23;
own unpublished observation).
In the rat brain, agmatinase, an enzyme responsible for
the inactivation of the putative neurotransmitter/
neuromodulator agmatine (recently reviewed in ref.24), is
prominently expressed in the MHb and the triangular
septum25. Additionally, the expression of agmatinase is
signiﬁcantly upregulated in the MHb of depressed
patients26 (→link to article). These observations led us to
hypothesize, that the agmatinergic system may be a part
of the information processing in the
septal–habenular–interpeduncular axis. This postulation
is supported by several further lines of evidence. Agma-
tine as well as the habenular systems are involved in
depression27–31 and anxiety18,32–35. Although to date the
LHb rather than the MHb has been discussed in the
context of depression, there is accumulating evidence for
an involvement for the MHb. Furthermore both, the LHb
and the MHb, display structural abnormalities with
respect to reduced volumes in patients suffering from
affective disorders when compared to controls or patients
with schizophrenia36. In contrast to the mainstream cor-
tical theory of mood disorders37, a recent commentary by
Loonen and Ivanova attempted to integrate the putative
roles of LHb and MHb in depression and anxiety in
subcortical forebrain and upper brainstem38.
Indeed, quite a number of experimental and clinical
reports indicate that the cerebral serotonin system is
critically involved in mood regulation. In this context,
there is increasing evidence for the involvement of a
dysbalanced serotonin system in the pathophysiology of
depression39,40. Consequently, the question arises whether
the involvement in depression is a direct effect of agma-
tine or rather mediated by the serotonergic system. In this
context, Zomkowski et al. reported evidence for serotonin
receptor involvement in an agmatine antidepressant like-
effect in mouse41. However, Krass and colleagues
demonstrated that the antidepressant-like effect of
agmatine in the forced swimming test is not mediated by
serotonin42.
In order to shed more light on the biological function of
the agmatinergic system in the MHb, we have investigated
the inﬂuence of agmatine and relevant imidazoline
receptor (I1, I2) antagonists/agonists on spontaneous
activity in neurons within the rat MHb. With regard to
the roles of the agmatinergic and habenular systems in
depression and anxiety, we extended our previous
immunocytochemical studies on agmatinase protein
expression in rat brain gaining additional insight into
agmatinase expression in humans using post-mortem
brains. The main goal of the present study was to obtain
an electrophysiological evidence for a potential mechan-
ism explaining the involvement of the agmatinergic sys-
tem with psychiatric disorders, notably major depression.
In order to extend our previous evidence for a dysregu-
lation of the agmatinergic system in the MHb of depres-
sed individuals26, we herein compared the distribution
pattern for agmatinase within the rat and human MHb.
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Materials and methods
Procedures of electrophysiological experiments
Slice preparation
Brain slices were prepared from 20 to 28 day post-
partum (P20–28) male Wistar rats obtained from an
institutional breeder (Forschungseinrichtungen für
Experimentelle Medizin, Charite-Universitätsmedizin
Berlin). Specimens were maintained under controlled
temperature (22 °C) and scheduled illumination (12 h
light/dark cycle) conditions with water and food ad libi-
tum. All experiments were approved by the Regional
Animals Ethics Committee (LaGeSo No.T 0127/02) and
performed in strict accordance with the European Com-
munities Council directive regarding care and use of
animals for experimental procedures. All efforts were
made to minimize the number of specimens and animal
suffering. The animals were deeply anesthetized with
isoﬂurane and then decapitated. Subsequently, the brains
were dissected and transferred into 4 °C cold artiﬁcial
cerebrospinal ﬂuid (ACSF; see below). Coronal slices
(400 µm thickness) containing the habenular complex
were cut using a vibrating microtome (VT 1000S; Leica
Instruments, Nussloch, Germany) and transferred into an
interface-type recording chamber continuously perfused
at a rate of 2.5–5.0 ml/min with prewarmed (34 °C) oxy-
genated ACSF containing in (mM): 125 NaCl, 25
NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 2 MgCl2, and
25 D-glucose, pH 7.4 maintained by saturation with car-
bogen (95% O2/5% CO2). In the ASCF solution used for
brain preparation and during slicing, 50 mM sucrose was
substituted for NaCl (to a ﬁnal concentration of 75 mM).
In addition, this solution contained (in mM): 0.1 CaCl2, 6
MgCl2, and 3 kynurenic acid (Sigma-Aldrich, now Merck;
Merck KGaA, Darmstadt, Germany) to suppress trans-
mission in the neuronal tissue. Before recording, the slices
were allowed to recover within the recording solution
(normal ACSF) for at least 1 h.
Electrophysiological recordings and data acquisition
Extracellular recordings were performed with glass
micropipettes made from borosilicate glass tubing (outer
diameter, 1.5 mm; wall thickness, 0.64 mm; Science Pro-
ducts, Hofheim, Germany) using a Sutter micropipette
puller (P-97; Sutter Instruments, Novato, CA, USA).
When ﬁlled with 0.5M potassium acetate, pipettes resis-
tances amounted to 5–10MΩ. Single-unit activity was
recorded using EXT-01C ampliﬁers (NPI Instruments,
Tamm, Germany). Extracellular spikes were acquired with
a CED 1401 plus interface (Cambridge Electronic Design
Limited, Cambridge, UK) controlled by Spike2 software
(CED Limited). The signals were digitized at 10 kHz and
bandpass ﬁltered at 0.3 and 3 kHz cutoff frequency. Once
single-unit activity was achieved, spontaneous ﬁring was
monitored over 5–10min to establish a stable baseline
prior to the recording session.
Perfusion compounds (PC)
Brain slices were perfused with the following PC:
agmatine sulfate (2 mM), moxonidine hydrochloride
(100 µM), efaroxan hydrochloride (100 µM), and idazoxan
hydrochloride (100 µM). All PC were purchased from
Sigma-Aldrich (now Merck; Merck KGaA, Darmstadt,
Germany). PC-containing solutions were freshly prepared
prior to the experiments. They were diluted in ACSF from
stock solutions dissolved in distilled water. Bath applica-
tion was achieved via the perfusion system of the
recording chamber.
Data analysis and statistics
Data analysis was done off-line using Spike2 (CED
Limited) and Origin 6.0 (MicroCal, Northampton, MA,
USA) software. Frequency histograms, number of spikes
per second, mean ﬁring rate, and percentage change from
control (baseline) activity were determined for each
experimental protocol. Each single-unit was evaluated for
an increase or decrease in ﬁring rate by comparing 15-min
time intervals of activity (i) before pharmacological
treatment (control), (ii) during PC administration, and
(iii) after washout. For analysis, the time intervals were
subdivided into 3-min bins. Experimental data were
normalized to the initial basal ﬁring rate for each single-
unit. Basal ﬁring was estimated as the frequency at the 3-
min interval before treatment and taken as 100%. The PC
bin interval containing the maximal change of frequency
was reported as drug effect, whereas washout was esti-
mated as the ﬁring frequency within the very last interval
of the respective washout phase. All numerical data are
reported as mean ± S.E.M. To evaluate the statistical sig-
niﬁcance, data were subjected to Student’s t-test (Origin
6.0 software; Microcal, Northampton, MA, USA). A
probability value of P ≤ 0.05 was considered to be
signiﬁcant.
Histological and immunocytochemical techniques
All animal experiments were conducted in accordance
with the guidelines of the European Communities Council
directive 86/609/EEC and were approved by the Regional
Berlin Animals Ethics Committee (LaGeSo No. G 0168/
01). For immunocytochemistry, adult male Wistar rats
were deeply anesthetized using a mixture of Ketavet
(Parke-Davis, now Pﬁzer, New York, NY, USA) and
Domitor (Pﬁzer). The animals were then perfused trans-
cardially with 0.9% NaCl solution for 1 min followed by a
ﬁxative composed of 4% paraformaldehyde, 0.05% glu-
taraldehyde, and 0.2% picric acid for 20min. For immu-
noﬂuorescence, 4% paraformaldehyde only was used as a
ﬁxative. Brains were then removed from the skull. Tissue
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was rinsed extensively in 0.1M phosphate buffer, and
then freeze-protected with 1M sucrose in 0.1M phos-
phate buffer. Thereafter, tissue was frozen at −60 °C in
hexane and stored frozen at −80 °C until use. For
immunocytochemistry, a total of three rats and 90 frontal
sections were analyzed. Immunocytochemical double-
labeling experiments were performed 3–5 times for each
combination of antigens.
Preparation of human tissue
All brains were obtained from pathologists or from
medical examination ofﬁcers, with the full consent of each
family and in accordance with the ethics and rules out-
lined by German law and the local ethics commission of
the University of Magdeburg. Brains of four individuals
without neurological or psychiatric disorders (two males,
54 and 63 years; two females, 54 and 61 years) were stu-
died. Brains were removed between 9 and 41 h after death.
Tissue preparation was performed as described pre-
viously43. Brieﬂy, brains were ﬁxed in-toto in 8%
phosphate-buffered formaldehyde (pH 7.0) for 2 months.
After embedding the brains in Paraplast (McCormick
Scientiﬁc, St. Louis, MO, USA), serial coronal 20-µm-
thick sections were cut on a microtome and mounted on
slides. Every 50th section was stained for morphological
orientation (combined Cresyl Violet and myelin staining
according to Nissl and Heidenhain-Woelcke).
Immunoperoxidase
Labeling was performed using standard diaminobenzi-
dine/nickel-immunoperoxidase protocols as described
previously44. Free-ﬂoating sections were treated with 1%
sodium-borohydride in phosphate-buffered saline (PBS)
for 15min, washed with PBS, and incubated in a solution
containing 10% normal goat serum (NGS), 0.3% Triton X-
100, and 0.05% phenylhydrazine in PBS for 30min. The
characterization of the anti-agmatinase antibody was
previously described25. It was diluted 1:1000 and 1:250,
respectively, in 10% NGS, 0.3% Triton X-100 supple-
mented with 0.1% sodium azide and 0.01% thimerosal,
and incubated for 36 h at 8 °C. Likewise, the anti-
calretinin antibody (1:15,000, AB1550, raised in goat;
Chemicon, Temecula, CA, USA) was applied.
After washing for 1 h in PBS and another hour in PBS
containing 0.2% bovine serum albumin (PBS/BSA), the
sections were incubated in biotinylated secondary goat
anti-rabbit antibody (Vector, 1:2000 in PBS/BSA) for 24 h
at 8 °C. The sections were again washed as described
above and further incubated for 6 h with an avidin-
biotinyl-peroxidase-complex (Vector Elite ABC kit) in
PBS/BSA. After the ﬁnal washing, bound peroxidase was
visualized in a solution containing 1.4 mM diamino-
benzidine, 10 mM imidazole, 6.6 mM nickel ammonium
sulfate, and 0.15% H2O2 in 50 mM Tris/HCl buffer, pH
7.4. All sections were developed for 15min. Labeled sec-
tions were mounted, dehydrated, and cover-slipped with
Entellan.
Immunoﬂuorescence
The incubation protocol used for immunoﬂuorescence
labeling (applies to supplemental ﬁgure S2) of rat brain
tissue was identical with the immunoperoxidase protocol
except for phenylhydrazine which was not used. Also
normal donkey serum instead of NGS was used as a
blocking reagent. Secondary antibodies used were goat
anti-rabbit CY3, goat anti-mouse CY2, and donkey anti-
goat CY2. Labeled sections were mounted on slides, air-
dried, dipped in xylene, and cover-slipped with DPX. For
double-labeling experiments, commercial antibodies
against calretinin45,46 (1:15,000, AB1550, raised in goat;
Chemicon, Temecula, CA, USA), parvalbumin47 (1:5000,
P-3171, raised in mouse; Sigma, St Louis, MO, USA),
calbindin48 (1:5000, C-8666, raised in mouse; Sigma),
were used. For controls, either primary or secondary
antibodies were omitted. No labeling was detected under
these conditions.
Anterograde tracer injections
Two adult Wistar rats (264 and 275 g body weight) were
anesthetized with 2–3% Isoﬂurane in 100% O2 and placed
in a stereotactic frame (David Kopf, Tujunga, CA, USA).
An isoﬂurane–O2 –mix was continuously delivered
through a rat anesthesia mask (David Kopf). Core body
temperature was monitored and maintained at 37 °C using
a feedback‐controlled heating blanket. An access hole was
made into the skull to unilaterally aim for the triangular
septum according to a rat brain atlas. For the tracer
injection, a glass pipette with end opening of 20 µm ﬁlled
with 10% biotinylated dextran amine (BDA) was lowered
into the brain at a 10° angle according to the following
coordinates: Bregma −0.8 mm; lateral: +0.6 mm, distance
from dura surface: −4.8 mm. BDA was ionotophoretically
injected over 30 min. For pre- and post-injection, the
electrode was maintained at position for 5 min. Finally,
the pipette was removed from the brain and the scalp was
closed with surgical sutures. Anesthesia was discontinued,
and after recovery, the rats were transferred to their home
cages. Three weeks later, the rats were deeply anesthetized
by intraperitoneal injection of a mixture of 45 volume
fractions ketamine hydrochloride (100 mg/ml; DeltaSe-
lect, Pfullingen, Germany), 35 volume fractions xylazine
hydrochloride (20 mg/ml; BayerVital), and 20 volume
fraction saline 0.9%. This mixture was dispensed at a dose
of 0.16 ml/100 g body weight. In addition, 200 IU heparin
sodium (Heparin‐Rotexmedica, Trittau, Germany) were
administered intraperitoneally to prevent blood clotting
during perfusion. Anesthetized rats were transaortically
perfused for 10 s with body-temperature warm plasma
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substitute (Deltadex 60; DeltaSelect), followed by 0.1M
phosphate buffer (pH 7.4) containing 4% paraformalde-
hyde, 0.05% glutaraldehyde, and 0.2% picric acid for
20min. After a ﬁnal 5‐min ﬂush of the vasculature with
0.15M sucrose in 0.1M phosphate buffer (pH 7.4), the
brains were removed, immersed in 0.8M sucrose over-
night for cryoprotection, sagittaly cut into blocks which
were shock-frozen in hexane at −70 °C, and subsequently
stored at −80 °C until they were serially cut into 25‐μm-
thick sections. Thereafter, individual series were pro-
cessed for light microscopic visualization of BDA. Free
ﬂoating sections were washed in PBS containing 0.2% BSA
(PBS-A) and 0.3% Triton, incubated overnight at 4 °C with
peroxidase-labeled streptavidin (NEL 750; PerkinElmer,
Rodgau-Jügesheim, Germany) diluted 1:20,000 in PBS-A.
Next, sections were rinsed in PBS and pre-incubated in a
solution containing 0.05% 3,3′-diaminobenzidine and
10mM imidazole in Tris buffer (50 mM, pH 7.6). Next,
ammonium nickel sulﬁte at 0.3% was added to the solu-
tion. The peroxidase reaction was started by the addition
of hydrogen peroxide at a ﬁnal concentration of 0.0015%.
After 10–15min under visual control, the reaction was
stopped by repeated washes in PBS. Finally, sections were
mounted onto gelatin-coated slides, dehydrated in a gra-
ded series of alcohol, cleared in xylene, and cover slipped.
Digital images (applies to supplemental ﬁgure S4) of the
slides were taking with an upright Leica DMRB light
microscope connected to a high‐resolution digital camera
(MBF‐CX9000; MBF Bioscience, Williston, VT). Images
were adjusted for brightness and contrast in Adobe
Photoshop CS3 and arranged in Adobe Illustrator CS3.
Retrograde tracer injections
Two further rats received microinjections aimed for the
ventrolateral IPN/parainterfascicular nucleus of the VTA
with the retrograde tracer gold-coupled wheatgerm
agglutinin (WGA-apoHRP-gold; 15-nm particle size;
10–20 μg/ml in distilled H2O, pH 7.0–7.5; E-Y Labora-
tories, San Mateo, CA). Anesthesia, glass capillaries, and
animal preparation were identical to the above-described
tracer injections with the following stereotactic aim
coordinates used: 5.8 mm posterior to bregma, 0.5 mm
from the midline, and 8.0 mm ventral to the dura. Careful
pressure application was used to inject approximately
0.3 µl tracer. The capillary was held in place for an addi-
tional 10 min before retrieving from the brain. After the
wounds were closed and anesthesia discontinued, the
animals were allowed to recover in their home cage. After
5 days, the animals were sacriﬁced, their brains were
quickly removed, and they were processed for subsequent
sectioning as described above (applies to supplemental
ﬁgure S4). WGA-apoHRP-gold tracer was visualized in
the section using a silver enhancement protocol49.
Results
Electrophysiology
The physiological data presented in this study are based
on extracellular single unit recordings obtained from 110
neurons within the MHb in slice preparations of 30 rats
(Fig. 1a). MHb neurons displayed spontaneous discharge
of action potentials at a mean ﬁring rate of 9.5 ± 1.0 Hz in
a range from 1 to 20 Hz. With respect to the pattern of
discharge, MHb neurons both exhibited regular tonic
ﬁring of action potentials or repetitively discharged single
action potentials randomly distributed (Fig. 1b, left
panels). Characteristically, the recorded MHb neurons
generated trains of broad (duration > 3ms), triphasic
extracellular spikes (Fig. 1b, right panels).
Agmatine suppresses spontaneous action potential ﬁring
in rat MHb neurons
To investigate, whether the rat MHb underlies poly-
aminergic modulation, we tested the effects of agmatine
on the basal ﬁring rate of individual MHb neurons. Bath
application of agmatine (2 mM) markedly suppressed
spontaneous action potential ﬁring of MHb neurons. A
typical response is illustrated in Fig. 1c. Here, the dis-
charge of the recorded neuron decreased from
15.1 spikes/s under control conditions to 5.2 spikes/s with
agmatine (Fig. 1d). Similar results were obtained in
another 12 neurons. In six neurons, agmatine slightly
increased action potential ﬁring, whereas in one recorded
cell, neuronal activity was not altered. On average,
agmatine decreased the mean ﬁring rate of MHb neurons
to 71.1 ± 5.5% of control (P ≤ 0.002, n= 13, Fig. 1e). The
effect appeared within 1.5–3min after application of the
perfusion compound, reached a maximum at about
10min after application, and was partially reversible with
discharge recovering slowly upon washout within 30 min
to 1.5 h (Fig. 1f).
Depression of MHb neuron discharge is mimicked by the
imidazoline-receptor agonist moxonidine
To evaluate the biological relevance of the agmatine
action onto spontaneous neuronal activity in rat MHb, we
examined the inﬂuence of moxonidine, an agonist of
endogenous imidazoline receptors. Not otherwise than
agmatine, the imidazoline-receptor agonist distinctly
suppressed action potential ﬁring of MHb neurons
(Fig. 2a). The quantiﬁcation of the observed effect for the
experiment illustrated in Fig. 2a revealed a decrease of
discharge from 4.1 spikes/s under control conditions to
1.3 spikes/s with moxonidine (100 µM, Fig. 2b). Similar
results were obtained in another 12 neurons. In three
neurons, action potential ﬁring was slightly enhanced. In
total, the reduction of mean ﬁring rate with moxonidine
amounted to 61.8 ± 5.3% of control (P ≤ 0.001, n= 13,
Fig. 2c). Although the agmatine-mediated reduction of
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Fig. 1 (See legend on next page.)
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spontaneous discharge was weaker (by approx. 29% with
agmatine vs. 38% with moxonidine), the two effects were
not signiﬁcantly different (P= 0.14). As observed with
agmatine, the moxonidine effect emerged within minutes
after onset of treatment, reached a maximum at about
10min after application, and was partially reversible upon
prolonged washout (Fig. 2d).
Suppression of MHb neuron activity is mediated via I1-like
imidazoline receptors
To elucidate the imidazoline receptor subtype involved
in the depression of spontaneous action potential ﬁring in
MHb neurons, we examined the effects of selective
antagonists of the imidazoline 1 (I1-like) and imidazoline
2 (I2-like) receptor, respectively.
First, we examined the inﬂuence of efaroxan, an inhi-
bitor of the I1-like receptor on both agmatine- and
moxonidine-mediated suppression of spontaneous dis-
charge. As illustrated in Fig. 3, pretreatment (15 min) with
the I1-antagonist efaroxan (100 µM) had no detectable
effect on action potential ﬁring of individual MHb neu-
rons (Fig. 3a, b, middle traces). However, efaroxan
strongly counteracted the depressant action of agmatine
and moxonidine, respectively. Neither co-application of
agmatine nor moxonidine with efaroxan altered MHb
neuron discharge (Fig. 3a, b, lower traces). For the
example shown in Fig. 3a, it is obvious from the respective
time histogram that the ﬁring rate of the recorded neuron
was unchanged amounting to about 15 spikes/s under
control, with efaroxan alone as well as with efaroxan and
agmatine (Fig. 3c). Thus, efaroxan completely blocked the
agmatine effect. Similar effects were observed in another
nine MHb neurons. On average, mean ﬁring rate after co-
application of agmatine with efaroxan was slightly, but not
signiﬁcantly, decreased to 98.4 ± 2.3% of control (P=
0.439, n= 10, Fig. 3e), a value which did not differ from
that obtained with efaroxan alone (97.4 ± 3.7%, P= 0.55)
or after washout (98.6 ± 1.9%, P= 0.78), respectively.
In the same way, efaroxan blocked the moxonidine-
mediated suppression of action potential ﬁring of MHb
neurons. In the case of the recorded neuron illustrated in
Fig. 3b, neither pretreatment with the I1-antagonist
(100 µM) nor subsequent co-application of efaroxan and
moxonidine altered spontaneous ﬁring. Here, basal ﬁring
rate amounted to 7.3 spikes/s under control conditions,
7.6 spikes/s with efaroxan alone, and 7.3 spikes/s with co-
application of efaroxan and moxonidine (Fig. 3d), indicating
a complete inhibition of the moxonidine effect. Similar
results were obtained in another eight recordings. On
average, mean ﬁring rate of MHb neurons during simulta-
neous treatment with efaroxan and moxonidine amounted
to 102.3 ± 7.9% of control (n= 9, Fig. 3f). This value did not
differ from that obtained with efaroxan alone (102.0 ± 3.2%,
P= 0.53) and after washout (94.8 ± 5.2%, P= 0.084).
Secondly, we investigated the effect of idazoxan, an
inhibitor of the I2-like receptor on agmatine- and
moxonidine-mediated depression of action potential ﬁr-
ing of neurons within the rat MHb. As observed for the
I1-like antagonist efaroxan, pretreatment of slices with
idazoxan (100 µM) had no detectable effects on sponta-
neous discharge of MHb neurons (Fig. 4a, b, middle tra-
ces). However, in contrast to efaroxan, the I2-antagonist
did not prevent the suppressive effect of agmatine and
moxonidine onto the ﬁring rate of MHb neurons. Thus, as
shown in Fig. 4a (lower trace), co-application of agmatine
(2 mM) and idazoxan (100 µM) distinctly suppressed
spontaneous discharge of individual MHb neurons. The
quantiﬁcation of the observed effect on the recorded
neuron revealed a decrease of ﬁring from 12.5 spikes/s
under control conditions to 7.5 spikes/s with the two
perfusion compounds (Fig. 4c). Similar results were
obtained in another seven recordings. In three recordings,
administration of idazoxan and agmatine slightly
increased action potential ﬁring. On average, the co-
application of agmatine and idazoxan signiﬁcantly
reduced the mean ﬁring rate to 62.2 ± 4.6% of control (P ≤
0.003, n= 8, Fig. 4e), which is not different (P= 0.58)
from the value observed with agmatine alone
(71.1 ± 5.5%).
Likewise, idazoxan failed to block the moxonidine effect
on action potential ﬁring of MHb neurons. A typical
response to co-application of moxonidine and idazoxan is
(see ﬁgure on previous page)
Fig. 1 Agmatine suppresses spontaneous action potential ﬁring within the rat MHb. a Photomicrograph of a coronal section (400-µm thick) of
rat diencephalon comprising the habenular complex. Inset at higher magniﬁcation focuses on the arrangement of the recording electrodes for that
triple recording. CC corpus callosum, CTX cortex, Hb habenular nucleus, HPF hippocampal formation, LHb lateral habenular complex, MHb medial
habenular complex, rE1–3 recording electrodes, TH thalamic nucleus. b Examples of representative extracellular recordings from tonic regular (upper
trace) and irregular (lower trace) ﬁring MHb neurons. Expansions of the respective recordings shown at the right illustrate shape and time course of
action potentials on enlarged time scales. c Representative recordings from another MHb neuron within a slice under control conditions (top trace)
and with bath-applied agmatine (bottom trace). d Rate histogram (bin width 60 s) obtained from the experiment shown in c illustrating the
agmatine-induced decrease in spontaneous action potential ﬁring of the neuron. Note the recovering of discharge upon washout. e Bar graph
summarizing the quantiﬁed data for the agmatine effect. Asterisk indicates a signiﬁcance level of P ≤ 0.04 (n= 13). f Time course response diagram
representing the results for the effect of agmatine on discharge frequency of 13 recorded MHb neurons. Normalized data are plotted as mean ﬁring
rate ± S.E.M. Note the discontinuity of y-axis. Gray backgrounds in b and c denote the time frame of agmatine administration
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illustrated in Fig. 4b. In that neuron, the ﬁring rate
decreased from 10.3 spikes/s in control to 7.3 spikes/s
with idazoxan and moxonidine (Fig. 4d). Similar effects
were observed in another eight experiments. In four
neurons, action potential ﬁring was slightly enhanced. In
total, the reduction of mean ﬁring rate of MHb neurons
with moxonidine and idazoxan amounted to 58.0 ± 9.1%
of control (P ≤ 0.004, n= 9, Fig. 4f). This decline is not
different (P= 0.79) from that obtained with moxonidine
alone (61.8 ± 5.3% of control).
Fig. 2 . Agmatinergic suppression of spontaneous action potential ﬁring in the rat MHb is mimicked by the imidazoline-receptor agonist
moxonidine. a Representative recordings from a MHb neuron under control conditions (top trace) and following bath application of moxonidine
(lower trace). b Rate histogram (bin width 20 s) of the experiment illustrated in a showing the moxonidine-induced decrease of discharge in the
recorded neuron. c Bar graph summarizing the results for the moxonidine effect. Asterisks indicate a signiﬁcance level of P ≤ 0.01 (n= 13). d Time
course response diagram illustrating the effect of moxonidine on MHb neuron ﬁring obtained from 13 single-unit recordings. Normalized data are
plotted as mean ﬁring rate ± S.E.M. Note the discontinuity of y-axis
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There is experimental evidence that beyond acting on
imidazoline receptors, agmatine may interact with α2-
adrenergic receptor binding sites50. Also the imidazoline
receptor antagonists efaroxan and idazoxan have been
shown to exert effects on that receptor type51–53.
Therefore, we performed control experiments using
yohimbine, a selective α2-adrenergic antagonist, to
elucidate the possible involvement of α2-adrenergic
receptors with the agmatinergic depression of action
potential ﬁring in the rat MHb. Our preliminary data
indicate that an activation of α2-adrenergic receptors, in
contrast to imidazoline I1 receptors, may only insignif-
icantly account for the inhibition of action potential
discharge induced by agmatine and moxonidine. This
Fig. 3 Agmatine- and moxonidine-mediated suppression of spontaneous discharge of MHb neurons is potently blocked by efaroxan, an
I1-subtype imidazoline receptor antagonist. a Representative recordings from a MHb neuron in a slice under control conditions (top trace),
following administration of efaroxan (middle trace) and upon efaroxan co-applied with agmatine (bottom trace). b Single-unit recordings from
another slice under control conditions (top trace), following administration of efaroxan (middle trace) and upon efaroxan co-applied with
moxonidine (bottom trace). c and d Rate histograms (bin widths 30 s) obtained from the recordings shown a and b, illustrating the responses with
efaroxan alone and following co-application of the I1-receptor antagonist with agmatine and moxonidine, respectively. Arrow heads indicate the
onsets of the respective application of the perfusion compounds. e and f Bar graphs summarizing the results of the experiments on efaroxan acting
indicating a complete inhibition of both agmatine- (e, n= 10) and moxonidine- (f, n= 9) mediated suppression of action potential ﬁring in the MHb.
Normalized data are plotted as mean ﬁring rate ± S.E.M
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observation is in line with earlier investigations showing
that (i) agmatine is about 30-fold selective for I1-,
relative to α2-adrenoceptors54 and (ii) the high afﬁnity
component of platelet I1-binding sites displayed for
agmatine a 800- to 5000-fold selectivity over the dif-
ferent types of α2-adrenoceptors55.
Expression of the agmatinergic system in the MHb
The presence of agmatine in the neurons of the MHb
has previously been shown56. However, the expression of
agmatinase, one of the enzymes capable of inactivating
agmatine in the brain24, was considered to reveal putative
target areas of this neurotransmitter/neuromodulator in
Fig. 4 Agmatine- and moxonidine-mediated suppression of spontaneous discharge of MHb neurons is not altered by idazoxan, an I2-like
imidazoline receptor antagonist. a Representative recordings from a MHb neuron in a slice under control conditions (top trace), with idazoxan
(middle trace) and upon idazoxan co-applied with agmatine (bottom trace). b Single-unit recordings from another slice under control conditions
(top trace), with idazoxan (middle trace) and upon idazoxan co-applied with moxonidine (bottom trace). c and d Rate histograms (bin widths 30 s)
obtained from the recordings shown a and b, illustrating the responses with idazoxan alone and following co-application of the I2-receptor
antagonist with agmatine and moxonidine, respectively. Arrow heads indicate the onsets of the respective application of the perfusion compounds.
e and f Bar graphs summarizing the results of the experiments on idazoxan acting indicating the absence of any impact on both, agmatine- (e, n= 8)
and moxonidine- (f, n= 9) mediated suppression of action potential ﬁring in the MHb. Normalized data are plotted as mean ﬁring rate ± S.E.M.
Asterisks indicate a signiﬁcance level of P ≤ 0.05 each
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more detail25. Agmatinase was not only shown to be
strongly expressed in rat but also in human MHb25. Thus,
it may be speculated that similar patterns of activity with
spontaneous ﬁring of action potentials may also exist in
the human brain. To date, however, this has not been
experimentally veriﬁed. The similar differential distribu-
tion of agmatinase-positive ﬁbers and neurons in both rat
and human supports the notion of functional similarities.
The overall morphological appearance of the habenula is
similar in rat and human brain (Fig. 5a–c). However, due
to differential neocortical development, the relative posi-
tion of the habenula with respect to the hippocampus is
remarkably different. In the rat, agmatinase-like immu-
noreactivity was localized to the neuropil and a
Fig. 5 Agmatinase in the MHb. a Allen adult mouse brain reference atlas. b and c Allen adult human brain reference atlas100. Compared to the
rodent MHb (a, shown in red), the human MHb (b, c) is located in a similar position, lining the lateral wall of the third ventricle, directly attached to
the thalamus (purple). The relative position to the hippocampus (blue) is different due to the neocortical development in human brain. Image credit:
Allen Institute (colors were modiﬁed). In cresyl violet-stained sections (d), the rat MHb appears relatively homogeneous and densely populated with
neurons. Note the sharp border along the lower half of the nucleus (arrowhead). Agmatinase-like immunoreactivity (e) is mainly prominent in the
neuropil, unveiling a sub-compartmentalization of the nucleus (ventrolateral border is indicated by an arrowhead). In addition, a stretch of strongly
labeled neurons is evident in the upper lateral half (double arrowheads). The overall topography of neuropil and cell labeling is schematically
delineated (f). With labeling for calretinin (g), a similar population of neurons (arrowhead and inset) is evident. The human MHb (h–k) also displays a
heterogeneous agmatinase labeling pattern in frontal (h) and sagittal (i) sections, suggesting a similar sub-compartmentalization. A dense meshwork
of ﬁbers and terminals (j) forms a band of immunoreactivity clearly separated from the ventricular wall. Intensely labeled cell bodies are also evident
(arrowhead in k). Scale bars= 100 µm in d, e, g; 20 µm in inset in g; 200 µm in h, i; 50 µm in j, k
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subpopulation of habenular neurons located in the upper
lateral aspect of the MHb (Fig. 5d, e). The neuropil
labeling varied in intensity in distinct MHb areas.
Accordingly, two prominent areas were detected along
the ventricular border (schematically depicted in Fig. 5f).
Co-localization with calcium-binding proteins
Calcium-binding proteins represent markers widely
used to characterize neuronal populations57. When
comparing agmatinase-like immunoreactivity with cal-
dendrin (Fig. 5g), a calcium-binding protein which was
previously reported to co-localize with agmatinase in
other brain areas25, a similar stretch of immunopositive
neurons was observed. Similar to the rat, the human MHb
also displayed a prominent agmatinase-like immunor-
eactivity with distinctive subregions (Fig. 5h, k). The
neuropil contained numerous labeled ﬁbers and terminals
(Fig. 5i). Intensely labeled cell bodies were also evident,
but not as closely associated as in the rat (Fig. 5j).
In order to further characterize the neurochemical
topography within the MHb, we employed a number of
neurochemical markers displaying differential labeling
patterns in this area (see supplementary Fig. S3). Among
these markers, both calretinin and calbindin showed a
pattern similar to the agmatinase distribution (Fig. S3 J,K,
L). In addition to the MHb, this similarity in the dis-
tribution of the two calcium-binding proteins and agma-
tinase also applied for the LHb. Interestingly, both, the
main input and output systems of the MHb, the triangular
septum and the IPN, respectively, also prominently
express agmatinase, as well as calretinin (Fig. S1 G-L). In
order to further verify the overlap in the expression of
agmatinase, calretinin, and calbindin in the same popu-
lation of neurons, we employed immunoﬂuorescence
double labeling (Fig. S2). In addition to a co-localization
of agmatinase and calretinin (Fig. S2 C, D), both the co-
localization of agmatinase and calbindin (Fig. S2 A,B) as
well as of calretinin and calbindin (Fig. S2 E,F) were
observed in individual neurons. The connectivity of the
MHb was previously analyzed5,6,14. We re-evaluated this
network with anterograde and retrograde labeling (see
Fig. S4).
Discussion
In the epithalamus, the habenulae represent the relay
station connecting limbic forebrain structures with mid-
brain diffuse neurotransmitter systems, including the
dopaminergic and serotoninergic systems. Within this
relay station, the MHb and the LHb form separate entities
with regard to morphology, connectivity, and electrical
activity. Both nuclei, however, consist of several subnuclei,
indicating further complexity of the involved circuits.
Despite this morphological and neurochemical hetero-
geneity, neurons within either the LHb on one hand and
the MHb, on the other, are characterized by similar pat-
terns of electrical activity. While lateral habenular neu-
rons produce action potentials in burst mode upon
activation, a signiﬁcant fraction of MHb neurons spon-
taneously generates tonic trains of action potentials8,58.
When compared with previous studies8,59, the mean fre-
quency of action potential trains measured in this study,
however, was obviously higher [9.5 Hz (1–20 Hz) as
compared to 5.0 Hz (1–10 Hz; ref.8) and 4.2 Hz (2–10 Hz;
ref.59)]. The latter study also revealed that cholinergic, but
not peptidergic, neurons show spontaneous action
potential ﬁring.
With respect to neurotransmitter release, the dorsal
component of the MHb was shown to express substance
P60, while the ventral component accounts for acet-
ylcholine release in the IPN61. In addition to acetylcholine
and substance P, glutamate is also released by MHb
projection neurons in the IPN14. Glutamate, in addition to
ATP, is also released in the MHb by axons arising from
the triangular septum14. Furthermore, genetic ablation of
MHb neurons led to a massive reduction of acetylcholine
in the IPN and a variety of behavioral abnormalities62.
Thus, any interference with cholinergic and glutamatergic
signaling in the dorsal diencephalic conduction system
can be expected to signiﬁcantly inﬂuence the balance of
limbic circuits. Agmatine is known to interact with both,
cholinergic and glutamatergic, systems. It blocks exocy-
tosis in chromafﬁn cells by blocking nicotinic acetylcho-
line receptor currents63 and is involved with nicotine64,
morphine65, and ethanol66 withdrawal. With respect to
glutamate receptors, agmatine has been shown to antag-
onize the NMDA subclass in a concentration- and
voltage-dependent manner in the hippocampal neurons67.
Hence, the aforementioned withdrawal syndromes may be
related to glutamate signaling at NMDA-receptor-
containing synapses (reviewed in refs.24,68). In the pre-
sent study, we show that agmatine attenuates the tonic
ﬁring of action potentials in the MHb. Since the IPN is the
major target of the MHb and given that the IPN activity in
turn decreases the midbrain dopamine release69, it can be
concluded that agmatine may regulate the inhibitory
effect of the habenula–interpeduncular pathway on the
reward system. This idea is further supported by the fact
that agmatine seemingly acts as an endogenous anti-
depressant70 and a malfunction of the reward system is a
hallmark of depression71–73.
Since agmatine may interact with different receptor
types, including α2-adrenergic and imidazoline receptors,
we tested different agonists and antagonists in order to
characterize the nature of the suppression of tonic activity
in the MHb. Accordingly, the inhibitory effect is appar-
ently mediated by activation of imidazoline receptors of
the I1-subtype. Both imidazoline I1 and I2 receptor sub-
types have been reported to be expressed in neurons and
Weiss et al. Translational Psychiatry  (2018) 8:201 Page 12 of 16
astrocytes74. In the MHb, an imidazoline receptor protein
was immunocytochemically localized75. Also, [3H]-RS-
45041-190, a selective high-afﬁnity radio ligand for I2
imidazoline receptors, intensely labeled the MHb76.
Moreover, imidazoline I1 receptors (IRAS/nischarin; see:
© 2017 Allen Institute for Brain Science. Allen Mouse
Brain Atlas. Available from: http://mouse.brain-map.org/,
ISH experiment 69134550, P56 mouse, section no. 18,
accessed at 04/27/2018 12:50 pm) and imidazoline I2
receptors77 have both been localized to the MHb by
in situ hybridization. Furthermore, clonidine, an imida-
zoline and α2-adrenergic agonist78,79, was shown to
attenuate increased brain glucose metabolism during
naloxone-precipitated morphine withdrawal in the
MHb80,81. Similarly, agmatine prevented the naloxone-
precipitated abstinence syndrome in morphine-dependent
rats65. Thus, a role for agmatine acting via imidazoline I1
receptors in addiction, as well as possibly in depression,
may be hypothesized (reviewed in ref.24). In support of
our data, the involvement of I1 imidazoline receptors with
the antidepressant-like action of agmatine in mouse
models of depression has been elegantly demonstrated
using different behavioral tests82. Interestingly, the mouse
I1 receptor homolog IRAS/nischarin was found to be
downregulated in the prefrontal cortex of postmortem
brains from individuals with major depression who
received antidepressant drug treatment83. In subcortical
limbic structures, however, this may be different. In this
context, the role of the MHb-IPN-pathway in addiction
and mood regulation has been recently reviewed84.
With regard to the subnuclear organization of the MHb,
agmatinase-like immunoreactivity is found in a sub-
population of neurons in the dorsolateral aspect and dif-
fusely throughout the neuropil of the nucleus, but most
prominently in the ventromedial aspect (Fig. 5f).
According to our data from retrograde tracing in the rat
IPN (Fig. S4), the dorsal half of the MHb is apparently
connected to the lateral IPN, which in turn also contains
the most intense immunosignal for agmatinase within the
IPN (Fig. S1l). On the other hand, the ventral half of the
MHb is highly enriched with nicotinic acetylcholine
receptors85. For comparison, other markers like L-enke-
phalin, NK-A, and calbindin (see supplemental ﬁgure 1)
deﬁne areas within the MHb only partially overlapping
with the peptidergic dorsal and the cholinergic ventral
region. Thus, a revision of the originally morphologically
deﬁned subnuclei of the MHb may need a systematic
effort in order to integrate all known data regarding
putative functional subdomains. A recent
transcriptomic–anatomic study supports the idea of the
presence of novel subﬁelds86.
The etiology of major depressive disorder is undoubt-
edly complex and several pathophysiological mechanisms
have been intensely examined, including the monoamine
hypothesis, the glutamate hypothesis, genetic factors,
endocrine factors (notably the Hypothalamus-Pituitary-
Adrenal axis dysfunction), environmental stress factors,
and immunologic factors (reviewed in refs.87,88). However,
common therapies are frequently based on the inter-
ference with monoamine levels by using monoamine
oxidase inhibitors and serotonin re-uptake inhibitors.
Interestingly, a robust expression of the serotonin recep-
tor 5HT-4 was observed in the lower half of the MHb (5
hydroxytryptamine receptor 4; see: © 2017 Allen Institute
for Brain Science. Allen Mouse Brain Atlas. Available
from: http://mouse.brain-map.org/, ISH experiment
72119658, P56 mouse, section no. 29, accessed at 07/23/
2018 12:43 pm). This expression pattern is at least par-
tially overlapping with the most prominent labeling for
agmatinase within the MHb. In concordance, in the
hamster brain, a dense innervation of the MHb by 5-HT-
IR ﬁbers has been shown, in contrast to an only very-
sparse innervation from the dorsal and median raphe
nuclei89. Thus, it is tempting to speculate that therapy
with serotonin re-uptake inhibitors may interfere with the
agmatinergic system in this area. Noteworthy, also
monoamine oxidase is robustly expressed in the lateral
part of the MHb (MAO A; see: © 2017 Allen Institute for
Brain Science. Allen Mouse Brain Atlas. Available from:
http://mouse.brain-map.org/, ISH experiment 74750015,
P56 mouse, section no. 27, accessed at 07/25/2018
10:15 pm) and may be inhibited by agmatine under cer-
tain conditions90. In addition to serotonin and nor-
epinephrine, a diminished dopaminergic
neurotransmission and an impaired cholinergic trans-
mission are evidently involved in the pathophysiology of
major depression and of addiction91,92. To this end, the
habenula apparently acts as a central regulator of diffuse
neurotransmitter systems. While the LHb modulates
serotonin levels and norepinephrine release, the MHb
regulates acetylcholine and dopamine levels93,94. Given
that in congenitally helpless rats, an animal model for
depression, an elevated metabolism of 64–71% in the
habenula and of 25% in the interpeduncular nucleus (K,
L), were observed31, the habenular–interpeduncular axis
seems to represent a promising target for the develop-
ment of new therapeutic strategies. In this scenario, the
results presented here suggest that the pharmacologic
interference with the agmatinergic system may promise
great potential in order to develop related strategies.
Conclusion
In summary, we conclude that our electrophysiological
data support the idea that the agmatinergic system
inﬂuences brain function in addiction, anxiety, and
depression. Accordingly, the release of agmatine in the
MHb, acting on imidazoline I1 receptors, would lead to
decreased excitation of the IPN and hence to an increase
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of dopaminergic function in the midbrain. Besides the
relevance for depression, for more detailed information
on the role of agmatine in addiction and anxiety, we refer
to recent reviews24,68. Interestingly, anxiety increased the
activity of neurons in the IPN95. This activation during
nicotine withdrawal was mediated by increased cortico-
tropin releasing factor receptor-1 expression and signal-
ing, which in turn modulated glutamatergic input from
the MHb. Thus, there is evidence that both agmatine and
the MHb may play pivotal roles not only in depression but
also in anxiety and addiction. Similar to the LHb, the
MHb function probably has to be expected to fall into
several subsystems. The habenula on the whole likely
represents a bottleneck in the subcortical emotional brain
circuits. Consequently, deep brain stimulation in this area
has undergone preclinical and clinical trials96 (reviewed in
refs.97–99). Interference with the agmatinergic system,
however, may offer a pharmacological alternative to sur-
gical therapy. Currently, our electrophysiological experi-
ments are limited to normal (“not depressed”)
experimental animals. In the future, it will be interesting
to gain additional insight with similar experiments per-
formed with brains derived from animal models for
depression, like congenital helpless rats.
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